MPR rolls out revamped website

Share this article:
Monthly Prescribing Reference (MPR) has relaunched its website with a number of enhancements to functionality and design, as well as a new, easier-to-remember URL, www.eMPR.com.

The new site will continue to focus on drug information but now offers a beefed-up search capability that can filter information according to a number of different criteria, including relevance, therapeutic category and date.
Furthermore, accompanying each drug monograph is a series of related resource options, such as drug news, sponsored alerts, pharmacology notes, clinical charts, similar drugs and recent updates to the data. Also, users are now able to compare drugs, side by side.

The redesigned site is easier to navigate and now features links to related sites, such as www.myCME.com. It also offers a much wider range of options for sponsors.

Physicians have been using the print editions of MPR for more than 25 years, and Jim Pantaleo, MPR vice president and publisher, says the new site is part of an initiative to offer up-to-date, concise drug information to healthcare professionals during every part of their day and in the medium of their choice.

MPR is published by Prescribing Reference, Inc., part of Haymarket Media, which also publishes MM&M.
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Channel

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...